FHTX
FHTX
NASDAQ · Biotechnology

Foghorn Therapeutics Inc

$4.14
-0.06 (-1.43%)
As of Sep 20, 10:32 PM ET ·
Financial Highlights (FY 2026)
Revenue
28.59M
Net Income
-68,710,789
Gross Margin
Profit Margin
-240.3%
Rev Growth
+17.1%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 35.6% 35.6%
Operating Margin -279.5% -251.5% 5.1% 4.9%
Profit Margin -240.3% -228.3% 4.9% 5.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 28.59M 24.41M 271.86M 230.16M
Gross Profit 96.87M 82.01M
Operating Income -79,909,391 -61,395,297 13.80M 11.27M
Net Income -68,710,789 -52,791,284 13.33M 11.49M
Gross Margin 35.6% 35.6%
Operating Margin -279.5% -251.5% 5.1% 4.9%
Profit Margin -240.3% -228.3% 4.9% 5.0%
Rev Growth +17.1% +17.1% -6.6% +8.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 139.92M 178.86M
Total Equity 241.00M 245.51M
D/E Ratio 0.58 0.73
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -76,825,595 -62,305,203 20.13M 16.16M
Free Cash Flow 11.27M 12.60M